株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

米国の分子診断市場:検査件数予測および企業

United States Molecular Diagnostics Market, Test Volume Forecast & Companies: Oncology Test (Breast, Colorectal, Prostate) Infectious Diseases Test (Virology, HPV, HAI, Critical Care) Genetic Test (Blood Screening, Food Pathogen, Tissue Typing HLA)

発行 Renub Research 商品コード 300967
出版日 ページ情報 英文 146 Pages; 87 Figures; 4 Tables
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.24円で換算しております。
Back to Top
米国の分子診断市場:検査件数予測および企業 United States Molecular Diagnostics Market, Test Volume Forecast & Companies: Oncology Test (Breast, Colorectal, Prostate) Infectious Diseases Test (Virology, HPV, HAI, Critical Care) Genetic Test (Blood Screening, Food Pathogen, Tissue Typing HLA)
出版日: 2017年08月28日 ページ情報: 英文 146 Pages; 87 Figures; 4 Tables
概要

当レポートでは、米国の分子診断市場について調査し、市場の概要と件数、応用別の予測、企業別動向、市場の課題などをまとめ、概略下記の構成で取り上げております。

第1章 エグゼクティブサマリー

第2章 米国の分子診断市場:検査件数と予測

  • 市場および予測
  • 検査件数および予測

第3章 米国の分子診断市場および件数シェア

第4章 米国の分子診断市場および予測:応用別

  • 癌検査
    • 乳癌
    • 結腸直腸癌
    • 前立腺癌
    • その他
  • 感染症検査
    • ウイルス検査
    • HPV検査
    • HAI検査
    • 救急救命検査
  • 遺伝子検査市場
  • 血液スクリーニング市場
  • 食品病原菌検査市場
  • 組織型決定(HLA)検査市場

第5章 米国の分子診断検査件数:応用別

  • 癌検査
  • 感染症検査
  • 遺伝子検査市場

第6章 米国の分子診断市場:企業別

第7章 促進因子

第8章 課題

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

As the evolution of innovative technologies is happening in the field of research and medicine, molecular diagnostics is growing rapidly. United States molecular diagnostics market is projected to surpass US$ 9 billion by 2024. Molecular diagnostics system is one of the hopeful systems that enable automation of extraction of high-quality nucleic acids from a wide variety of sample types and the selection of targeted, individualized treatment options. Molecular diagnostics system offers early disease detection, potentially before symptoms have even occurred.

In this report United States molecular diagnostics market has been segmented into three major categories: Oncology Test, Infectious Disease Test and Genetic Disease Test. Further, Oncology Test has been segmented into four major categories: Breast Cancer Test, Colorectal Cancer Test, Prostate Cancer Test and Other Cancer Test. Infectious Disease Test has been segmented into four major categories, namely, Virology, HAI, HPV and Critical Care Test and Genetic Test has been segmented into Blood Screening, HLA and Food Pathogen Test.

United State Molecular Diagnostics Market Shares: Overview

Our study found that both the Oncology and Infectious Test market have significant market in United States Molecular Diagnostics Market. In Molecular Oncology Test market; Breast cancer dominates the market on the other side in Molecular Infectious Test market; Virology is leading all other segments. While in terms of Tests Volume; Genetics test is leading all way ahead from Infectious and Oncology Test owing to Food Pathogen Test Volume.

The top players in United States Molecular Diagnostics Market includes several familiar names such as Roche, Hologic, Becton Dickinson, Myraid Genetics, Qiagen and Abbott, Siemens, bioMérieux and Cepheid.

Renub Research study titled “United States Molecular Diagnostics Market, Test Volume Forecast & Companies: Oncology Test (Breast Cancer, Colorectal Cancer, Prostate Cancer, Others) Infectious Diseases (Virology Test, HPV Test, HAI Test, Critical Care Test) Genetic Test (Blood Screening, Food Pathogen Test, Tissue Typing HLA Test)&rldquo; provides a comprehensive assessment of the fast-evolving, high-growth United States Molecular Diagnostics Market. This is the 2nd edition of the report published by Renub Research.

This 146 page report with 87 Figures and 4 Tables studies the United States Molecular Diagnostics from 4 view points:

  • 1) Molecular Diagnostics Market and Forecast
  • 2) Segments Market & Forecast
  • 3) Segments Test Volume & Forecast
  • 4) Company Molecular Diagnostics Sales & Forecast

United States Molecular Diagnostics Market & Test Volume - Application Segment Analysis (2010 - 2024)

1. Oncology Test

  • a) Breast Cancer
  • b) Colorectal Cancer
  • c) Prostate Cancer
  • d) Others

2. Infectious Diseases

  • a) Virology Test
  • b) HPV Test
  • c) HAI Test
  • d) Critical Care Test

3. Genetic Test

  • a) Blood Screening
  • b) Food Pathogen Test
  • c) Tissue Typing (HLA Test)

Company Sales Analysis (2010 - 2024)

  • 1. Roche
  • 2. Abbott
  • 3. Myriad Genetics
  • 4. BioMerieux
  • 5. Qiagen
  • 6. Hologic Inc.
  • 7. Becton Dickinson
  • 8. Siemens
  • 9. Cepheid
  • 10. Others

Table of Contents

1. Executive Summary

2. United States Molecular Diagnostics Market & Forecast

3. United States Molecular Diagnostics Test Volume & Forecast

4. United States Molecular Diagnostics Market Share (2010-2024)

  • 4.1. Market Share & Forecast-(Oncology, Infectious, Genetics) Tests
  • 4.2. Segments Market Share & Forecast-(Breast, Colorectal, Prostate, Other) Cancer, (Virology, HAI, HPV, Critical Care, HLA, Blood Screening, Food Pathogen) Test
  • 4.3. Company Market Share-(Roche, Abbott, Myriad Genetics, BioMerieux, Qiagen, Hologic Inc., Becton Dickinson, Siemens, Cepheid, Others)

5. United States Molecular Diagnostics Test Volume Share (2010-2024)

  • 5.1. Volume Share & Forecast-(Oncology, Infectious, Genetics) Tests

6. Segments-United States Molecular Diagnostics Market (2010-2024)

  • 6.1. Oncology Test Market Share
  • 6.2. Oncology Test Market
    • 6.2.1. Breast Cancer Testing Market
    • 6.2.2. Colorectal Cancer Test Market
    • 6.2.3. Prostate Cancer Test Market
    • 6.2.4. Other Cancer Test Market
  • 6.3. Market Share-Infectious Disease Test
  • 6.4. Infectious Disease Test Market
    • 6.4.1. Virology Test Market
    • 6.4.2. HPV Test Market
    • 6.4.3. HAI Test Market
    • 6.4.4. Critical Care Test Market
  • 6.5. Genetic Test Market Share
  • 6.6. Genetic Test Market
    • 6.6.1. Blood Screening Market
    • 6.6.2. Food Pathogen Test Market
    • 6.6.3. Tissue Typing (HLA) Test Market

7. Segments-United States Molecular Diagnostics Test Volume (2010-2024)

  • 7.1. Oncology Test Volume Share
  • 7.2. Oncology Test Volume
    • 7.2.1. Breast Cancer Test Volume
    • 7.2.2. Colorectal Cancer Test Volume
    • 7.2.3. Prostate Cancer Test Volume
    • 7.2.4. Other Cancer Test Volume
  • 7.3. Infectious Disease Test Volume Share
  • 7.4. Infectious Disease Test Volume
    • 7.4.1. Virology Test Volume
    • 7.4.2. HPV Test Volume
    • 7.4.3. HAI Test Volume
    • 7.4.4. Critical Care Test Volume
  • 7.5. Genetic Test Volume Share
  • 7.6. Genetic Testing Test Volume
    • 7.6.1. Blood Screening Test Volume
    • 7.6.2. Food Pathogen Test Volume
    • 7.6.3. HLA Test Volume

8. Company-United States Molecular Diagnostics Sales & Forecast

  • 8.1. Roche
  • 8.2. Abbott Laboratories
  • 8.3. Myriad Genetics
  • 8.4. BioMerieux
  • 8.5. Qiagen
  • 8.6. Hologic Inc. (Acquired Gen-Probe)
  • 8.7. Becton Dickinson
  • 8.8. Siemens
  • 8.9. Cepheid
  • 8.10. Others

9. Growth Factors

  • 9.1. Growing Automation
  • 9.2. Rising Investment in Genomics & Proteomics Research
  • 9.3. Personalized Medicine Fuels Molecular Diagnostics

10. Challenges

  • 10.1. Regulatory Issues
  • 10.2. Reimbursement Capabilities
  • 10.3. Quality Checkpoints, Awareness & Acceptance

List of Figures

  • Figure 2-1: United States - Molecular Diagnostics Market (Million US$), 2010 - 2016
  • Figure 2-2: United States - Forecast for Molecular Diagnostics Market (Million US$), 2017 - 2024
  • Figure 2-3: United States - Molecular Diagnostics Test Volume (Million), 2010 - 2016
  • Figure 2-4: United States - Forecast for Molecular Diagnostics Test Volume (Million), 2017 - 2024
  • Figure 3-1: United States Molecular Diagnostics Market Share (Percent), 2010 - 2016
  • Figure 3-2: United States - Forecast for Molecular Diagnostics Market Share (Percent), 2017 - 2024
  • Figure 3-3: United States Molecular Diagnostics Test Volume Share (Percent), 2010 - 2016
  • Figure 3-4: United States - Forecast for Molecular Diagnostics Test Volume Share (Percent), 2017 - 2024
  • Figure 3-5: United States - Company Wise Molecular Diagnostics Market Share (Percent), 2010 - 2016
  • Figure 3-6: United States - Forecast for Company Wise Molecular Diagnostics Market Share (Percent), 2017 - 2024
  • Figure 4-1: United States - Molecular Diagnostic Oncology Testing Market (Million US$), 2010 - 2016
  • Figure 4-2: United States - Forecast for Molecular Diagnostic Oncology Testing Market (Million US$), 2017 - 2024
  • Figure 4-3: United States - Molecular Diagnostic Breast Cancer Testing Market (Million US$), 2004 - 2016
  • Figure 4-4: United States - Forecast for Molecular Diagnostic Breast Cancer Testing Market (Million US$), 2017 - 2024
  • Figure 4-5: United States - Molecular Diagnostic Colorectal Cancer Testing Market (Million US$), 2010 - 2016
  • Figure 4-6: United States - Forecast for Molecular Diagnostic Colorectal Cancer Testing Market (Million US$), 2017 - 2024
  • Figure 4-7: United States - Molecular Diagnostic Prostate Cancer Testing Market (Million US$), 2004 - 2016
  • Figure 4-8: United States - Forecast for Molecular Diagnostic Prostate Cancer Testing Market (Million US$), 2017 - 2024
  • Figure 4-9: United States - Other Molecular Diagnostic Cancer Testing Market (Million US$), 2004 - 2016
  • Figure 4-10: United States - Forecast for Other Molecular Diagnostic Cancer Testing Market (Million US$), 2017 - 2024
  • Figure 4-11: United States - Infectious Disease Testing Market (Million US$), 2010 - 2016
  • Figure 4-12: United States - Forecast for Infectious Disease Testing Market (Million US$), 2017 - 2024
  • Figure 4-13: United States - Virology Testing Market (Million US$), 2010 - 2016
  • Figure 4-14: United States - Forecast for Virology Testing Market (Million US$), 2017 - 2024
  • Figure 4-15: United States - HPV Testing Market (Million US$), 2010 - 2016
  • Figure 4-16: United States - Forecast for HPV Testing Market (Million US$), 2017 - 2024
  • Figure 4-17: United States - HAI Testing Market (Million US$), 2010 - 2016
  • Figure 4-18: United States - Forecast for HAI Testing Market (Million US$), 2017 - 2024
  • Figure 4-19: United States - Critical Care Testing Market (Million US$), 2010 - 2016
  • Figure 4-20: United States - Forecast for Critical Care Testing Market (Million US$), 2017 - 2024
  • Figure 4-21: United States - Genetic Testing Market (Million US$), 2010 - 2016
  • Figure 4-22: United States - Forecast for Genetic Testing Market (Million US$), 2017 - 2024
  • Figure 4-23: United States - Blood Screening Market (Million US$), 2006 - 2016
  • Figure 4-24: United States - Forecast for Blood Screening Market (Million US$), 2017 - 2024
  • Figure 4-25: United States - Food Pathogen Testing Market (Million US$), 2010 - 2016
  • Figure 4-26: United States - Forecast for Food Pathogen Testing Market (Million US$), 2017 - 2024
  • Figure 4-27: United States - HLA Testing Market (Million US$), 2008 - 2016
  • Figure 4-28: United States - Forecast for HLA Testing Market (Million US$), 2017 - 2024
  • Figure 5-1: United States - Oncology Test Volume (Million), 2010 - 2016
  • Figure 5-2: United States - Forecast for Oncology Test Volume (Million), 2017 - 2024
  • Figure 5-3: United States - Breast Cancer Test Volume (Million), 2004 - 2016
  • Figure 5-4: United States - Forecast for Breast Cancer Test Volume (Million), 2017 - 2024
  • Figure 5-5: United States - Colorectal Cancer Test Volume (Million), 2010 - 2016
  • Figure 5-6: United States - Forecast for Colorectal Cancer Test Volume (Million), 2017 - 2024
  • Figure 5-7: United States - Prostate Cancer Test Volume (Million), 2004 - 2016
  • Figure 5-8: United States - Forecast for Prostate Cancer Test Volume (Million), 2017 - 2024
  • Figure 5-9: United States - Other Cancer Test Volume (Million), 2004 - 2016
  • Figure 5-10: United States - Forecast for Other Cancer Test Volume (Million), 2017 - 2024
  • Figure 5-11: United States - Infectious Disease Test Volume (Million), 2010 - 2016
  • Figure 5-12: United States - Forecast for Infectious Disease Test Volume (Million), 2017 - 2024
  • Figure 5-13: United States - Virology Test Volume (Million), 2010 - 2016
  • Figure 5-14: United States - Forecast for Virology Test Volume (Million), 2017 - 2024
  • Figure 5-15: United States - HPV Test Volume (Million), 2010 - 2016
  • Figure 5-16: United States - Forecast for HPV Test Volume (Million), 2017 - 2024
  • Figure 5-17: United States - HAI Test Volume (Million), 2010 - 2016
  • Figure 5-18: United States - Forecast for HAI Test Volume (Million), 2017 - 2024
  • Figure 5-19: United States - Critical Care Test Volume (Million), 2010 - 2016
  • Figure 5-20: United States - Forecast for Critical Care Test Volume (Million), 2017 - 2024
  • Figure 5-21: United States - Genetic Testing Test Volume (Million), 2010 - 2016
  • Figure 5-22: United States - Forecast for Genetic Testing Test Volume (Million), 2017 - 2024
  • Figure 5-23: United States - Blood Screening Test Volume (Million), 2006 - 2016
  • Figure 5-24: United States - Forecast for Blood Screening Test Volume (Million), 2017 - 2024
  • Figure 5-25: United States - Food Pathogen Test Volume (Million), 2010 - 2016
  • Figure 5-26: United States - Forecast for Food Pathogen Test Volume (Million), 2017 - 2024
  • Figure 5-27: United States - HLA Test Volume (Million), 2008 - 2016
  • Figure 5-28: United States - Forecast for HLA Test Volume (Million), 2017 - 2024
  • Figure 6-1: Roche - United States Molecular Diagnostic Sales (Million US$), 2008 - 2016
  • Figure 6-2: Roche - Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 - 2024
  • Figure 6-3: Abbott Laboratories - United States Molecular Diagnostic Sales (Million US$), 2010 - 2016
  • Figure 6-4: Abbott Laboratories - Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 - 2024
  • Figure 6-5: Myriad Genetics - United States Molecular Diagnostic Sales (Million US$), 2007 - 2016
  • Figure 6-6: Myriad Genetics - Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 - 2024
  • Figure 6-7: Biomerieux - United States Molecular Diagnostic Sales (Million US$), 2010 - 2016
  • Figure 6-8: Biomerieux - Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 - 2024
  • Figure 6-9: Qiagen - United States Molecular Diagnostic Sales (Million US$), 2010 - 2016
  • Figure 6-10: Qiagen - Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 - 2024
  • Figure 6-11: Hologic-Gen-Probe - United States Molecular Diagnostic Sales (Million US$), 2010 - 2016
  • Figure 6-12: Hologic-Gen-Probe - Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 - 2024
  • Figure 6-13: Becton Dickinson - United States Molecular Diagnostic Sales (Million US$), 2010 - 2016
  • Figure 6-14: Becton Dickinson - Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 - 2024
  • Figure 6-15: Siemens - United States Molecular Diagnostic Sales (Million US$), 2008 - 2016
  • Figure 6-16: Siemens - Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 - 2024
  • Figure 6-17: Cepheid - United States Molecular Diagnostic Sales (Million US$), 2010 - 2016
  • Figure 6-18: Cepheid - Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 - 2024
  • Figure 6-19: Others - United States Molecular Diagnostic Sales (Million US$), 2010 - 2016
  • Figure 6-20: Others - Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 - 2024
  • Figure 7-1: United States - Investment in the Human Genome Project (Billion US$), 2003, 2012

List of Tables

  • Table 3-1: United States - Molecular Diagnostics Application Market Share (Percent), 2010 - 2016
  • Table 3-2: United States - Forecast for Molecular Diagnostics Application Market Share (Percent), 2017 - 2024
  • Table 3-3: United States - Molecular Diagnostics Application Test Volume Share (Percent), 2010 - 2016
  • Table 3-4: United States - Forecast for Molecular Diagnostics Application Test Volume Share (Percent), 2017 - 2024
Back to Top